Industry payments to oncologists were associated with increased use of the promoted cancer treatment, regardless of whether ...
The phase 2 EVITA trial (NCT03682029) was the first double-blind, randomized, placebo-controlled study of oral vitamin C in ...
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in ...
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma. The NCCN published its first ...
Matthew Gumbleton, MD, PhD, of Huntsman Cancer Institute rejects the idea that a TP53 co-mutation points toward chemotherapy ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated ...
With bispecifics, that’s extraordinarily rare. The incidence of ICANS with bispecifics is on the order of 5% or less, and ...
Boccia, MD, FACP, founder of The Center for Cancer and Blood Disorders, clinical associate professor at MedStar Georgetown ...
The FDA has granted fast track designation to VIR-5500, a prostate-specific membrane antigen (PSMA)-targeted PRO-XTEN® ...
The safety profile is one of the biggest advantages of CAR NK cells, and that is exciting for the field because NK cells do ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results